Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement.

Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement.

Many diabetic patients continue to have hyperglycaemia on maximal sulphonylurea therapy. Five different therapeutic options, with the prime aim of achieving normal fasting plasma glucose concentrations, have been compared in 15 asymptomatic, sulphonylurea-treated type 2 diabetic patients in a random...

Bibliografske podrobnosti
Main Authors:	Holman, R, Steemson, J, Turner, R
Format:	Journal article
Jezik:	English
Izdano:	1987

Podobne knjige/članki

TWICE-DAILY SUBCUTANEOUS HUMAN PROINSULIN PROVIDES A SATISFACTORY BASAL INSULIN SUPPLEMENT IN TYPE-2 (NON-INSULIN-DEPENDENT) DIABETIC-PATIENTS
od: Holman, R, et al.
Izdano: (1987)

Post-prandial amylin concentrations are increased by sulphonylurea, but unchanged by basal insulin, in NIDDM
od: Rachman, J, et al.
Izdano: (1996)

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years
od: Matthews, DR, et al.
Izdano: (1998)

UKPDS 18: Estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy
od: Eeley, E, et al.
Izdano: (1996)

COMPARISON OF TREATMENT OF MILD DIABETES WITH A BASAL INSULIN SUPPLEMENT OR SULFONYLUREA
od: Holman, R, et al.
Izdano: (1977)

Post-prandial glycaemic reduction by an alpha-glucosidase inhibitor in type 2 diabetic patients with therapeutically attained basal normoglycaemia.
od: Holman, R, et al.
Izdano: (1991)

Efficacy over six years of sulphonylurea plus insulin therapy in type 2 diabetic patients in the UKPDS
od: Cull, C, et al.
Izdano: (2000)

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.
od: Matthews, DR, et al.
Izdano: (1998)

NASAL INSULIN OUTPATIENT STUDY IN TYPE-I DIABETES
od: Holman, R, et al.
Izdano: (1992)

UKPDS 18: estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy. UK Prospective Diabetes Study Group.
od: Eeley, E, et al.
Izdano: (1996)

This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes
od: Ryder, R, et al.
Izdano: (2016)

Sulphonylureas in the management of type 2 diabetes: To be or not to be?
od: André J. Scheen
Izdano: (2021-01-01)

Beta-cell function improved by supplementing basal insulin secretion in mild diabetes.
od: Turner, R, et al.
Izdano: (1976)

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
od: Turner, R, et al.
Izdano: (1998)

TIMING OF NASAL INSULIN DELIVERY IN TYPE-I DIABETES
od: Holman, R, et al.
Izdano: (1993)

Permanent neonatal diabetes: combining sulphonylureas with insulin may be an effective treatment
od: Misra, S, et al.
Izdano: (2018)

Maintenance of basal plasma glucose and insulin concentrations in maturity-onset diabetes.
od: Holman, R, et al.
Izdano: (1979)

Differences in insulin treatment satisfaction following randomized addition of biphasic, prandial or basal insulin to oral therapy in type 2 diabetes.
od: Farmer, A, et al.
Izdano: (2011)

LACK OF BENEFIT FROM GUAR ADMINISTRATION IN WELL CONTROLLED NON-INSULIN-DEPENDENT DIABETIC-PATIENTS
od: Holman, R, et al.
Izdano: (1984)

Sulphonylurea therapy over six years does not delay progression to diabetes
od: Herlihy, O, et al.
Izdano: (2000)

HUMAN ULTRALENTE INSULIN
od: Holman, R, et al.
Izdano: (1983)

Intermediate acting insulin for type 2 diabetes.
od: Turner, R, et al.
Izdano: (1985)

Factors influencing utilization of different types of sulphonylureas amongst type 2 diabetes patients
od: Huri, H.Z., et al.
Izdano: (2010)

Induced basal normoglycemia and altered platelet aggregation in non-insulin-dependent diabetes.
od: Evans, R, et al.
Izdano: (1982)

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.
od: Holman, R, et al.
Izdano: (2007)

Sulphonylureas and hypoglycaemia.
od: Ferner, R, et al.
Izdano: (1988)

A practical guide to basal and prandial insulin therapy.
od: Holman, R, et al.
Izdano: (1985)

Human ultralente insulin.
od: Holman, R, et al.
Izdano: (1984)

Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations.
od: Turner, R, et al.
Izdano: (1979)

Insulin therapy in type II diabetes.
od: Holman, R, et al.
Izdano: (1995)

UKPDS - 6-YEAR TRIAL OF SULFONYLUREA, INSULIN AND METFORMIN THERAPY IN TYPE-2 DIABETIC-PATIENTS WITH DIET FAILURE
od: Cull, C, et al.
Izdano: (1995)

Identification of First Case of Neonatal Diabetes in Singapore and Successful Conversion from Insulin to Sulphonylurea
od: Rashida Vasanwala MD (Paeds), MRCPCH (UK), et al.
Izdano: (2010-06-01)

Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus
od: Fournier, Marie, et al.
Izdano: (2014-10-01)

Diabetes: The quest for basal normoglycaemia.
od: Holman, R, et al.
Izdano: (1977)

2-YEAR PROSPECTIVE-STUDY OF IMPROVED DIABETIC CONTROL IN INSULIN-DEPENDENT DIABETIC-PATIENTS WITH BACKGROUND RETINOPATHY
od: Holman, R, et al.
Izdano: (1982)

Rapid restoration of normoglycaemia using intravenous insulin boluses.
od: Dunnett, J, et al.
Izdano: (1990)

Basal insulin therapy in type 2 diabetes.
od: Bethel, M, et al.
Izdano: (2005)

Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?
od: Rodrigo Oliveira Moreira, et al.
Izdano: (2018-04-01)

Efficacy and safety of insulin lispro protamine suspension as basal supplementation in patients with type 2 diabetes
od: Dario Giugliano, et al.
Izdano: (2012-06-01)

Pharmacogenetics in Type 2 diabetes: variation in TCF7L2 influences response to sulphonylureas
od: Pearson, E, et al.
Izdano: (2007)